Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
37
ATRA Quote, Financials, Valuation and Earnings
Last price:
$14.17
Seasonality move
:
-2.1%
Day range:
$12.55 - $14.25
52-week range:
$5.01 - $18.71
Dividend yield:
0%
P/E ratio:
6.48x
P/S ratio:
1.11x
P/B ratio:
--
Volume:
127.4K
Avg. volume:
63.8K
1-year change:
14.61%
Market cap:
$102.4M
Revenue:
$128.9M
EPS (TTM):
$2.19
Analysts' Opinion
-
Consensus RatingAtara Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.33, Atara Biotherapeutics, Inc. has an estimated upside of 15.02% from its current price of $14.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $14.20.
Fair Value
-
According to the consensus of 5 analysts, Atara Biotherapeutics, Inc. has 15.02% upside to fair value with a price target of $16.33 per share.
ATRA vs. S&P 500
-
Over the past 5 trading days, Atara Biotherapeutics, Inc. has underperformed the S&P 500 by -4.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Atara Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Atara Biotherapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Atara Biotherapeutics, Inc. reported revenues of $3.5M.
Earnings Growth
-
Atara Biotherapeutics, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Atara Biotherapeutics, Inc. reported earnings per share of -$0.32.
Enterprise value:
147.3M
EV / Invested capital:
6.70x
Price / LTM sales:
1.11x
EV / EBIT:
3.92x
EV / Revenue:
0.97x
PEG ratio (5yr expected):
-0.16x
EV / Free cash flow:
-2.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
3.67x
Gross Profit (TTM):
$124M
Return On Assets:
30.72%
Net Income Margin (TTM):
15.4%
Return On Equity:
-2818.48%
Return On Invested Capital:
212.25%
Operating Margin:
-102.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.5M | $100.4M | $151.9M | $40.2M | $3.5M | |
| Gross Profit | -$13.5M | $83.1M | $124M | $32.6M | $3.3M | |
| Operating Income | -$291.5M | -$119.4M | $37.6M | -$21.8M | -$3.5M | |
| EBITDA | -$277.9M | -$114.2M | $40.2M | -$20.5M | -$3.5M | |
| Diluted EPS | -$18.52 | -$25.66 | $2.19 | -$2.93 | -$0.32 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $369.5M | $283M | $118.7M | $91.9M | $18.4M | |
| Total Assets | $449.9M | $368.3M | $188.8M | $142.7M | $30.2M | |
| Current Liabilities | $86.2M | $72.2M | $79.1M | $156M | $18.1M | |
| Total Liabilities | $139.8M | $181.2M | $239.6M | $233.2M | $66.8M | |
| Total Equity | $310.1M | $187.1M | -$50.8M | -$90.5M | -$36.6M | |
| Total Debt | $24.6M | $65.7M | $49.4M | $74.4M | $56.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$199.5M | -$94.7M | -$69.7M | -$4M | -$9.8M | |
| Cash From Investing | $165.1M | $15.2M | $13.1M | -$16.7M | -$2.4M | |
| Cash From Financing | $32.8M | $61.1M | $15.8M | $35.8M | $1M | |
| Free Cash Flow | -$200.7M | -$94.9M | -$69.8M | -$4M | -$9.8M | |
ATRA
Sector
Market Cap
$102.4M
$28.8M
Price % of 52-Week High
75.92%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-9.79%
-1.32%
1-Year Price Total Return
14.61%
-20.64%
Beta (5-Year)
-0.416
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.88
200-day SMA
Buy
Level
$10.15
Bollinger Bands (100)
Buy
Level
11.44 - 14.44
Chaikin Money Flow
Sell
Level
-1.8M
20-day SMA
Buy
Level
$13.32
Relative Strength Index (RSI14)
Buy
Level
53.24
ADX Line
Buy
Level
13.87
Williams %R
Neutral
Level
-33.4365
50-day SMA
Buy
Level
$14.04
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-28.0923)
Sell
CA Score
(Annual)
Level (-8.2495)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (14.3769)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Stock Forecast FAQ
In the current month, ATRA has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ATRA average analyst price target in the past 3 months is $16.33.
-
Where Will Atara Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Atara Biotherapeutics, Inc. share price will rise to $16.33 per share over the next 12 months.
-
What Do Analysts Say About Atara Biotherapeutics, Inc.?
Analysts are divided on their view about Atara Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atara Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Atara Biotherapeutics, Inc.'s Price Target?
The price target for Atara Biotherapeutics, Inc. over the next 1-year time period is forecast to be $16.33 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ATRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Atara Biotherapeutics, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ATRA?
You can purchase shares of Atara Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atara Biotherapeutics, Inc. shares.
-
What Is The Atara Biotherapeutics, Inc. Share Price Today?
Atara Biotherapeutics, Inc. was last trading at $14.17 per share. This represents the most recent stock quote for Atara Biotherapeutics, Inc.. Yesterday, Atara Biotherapeutics, Inc. closed at $14.20 per share.
-
How To Buy Atara Biotherapeutics, Inc. Stock Online?
In order to purchase Atara Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ATRA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ATRA
Sector
P/E ratio
6.48x
23.71x
PEG ratio
-0.16x
-0.01x
P/B ratio
--
1.84x
Price / LTM sales
1.11x
1.60x
Growth Metrics
ATRA
Sector
Revenue growth
-91.41%
4.85%
Earnings growth
89.19%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.67
-$0.20
Profitability
ATRA
Sector
Profitability FY 2024
$107.9M
$3.6M
Return on invested capital
212.25%
-30.98%
Return on assets
30.72%
-27.62%
Return on equity
-2818.48%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
11
Balance Sheet
ATRA
Sector
Total cash
$13.7M
$27.2M
Short term investments
$17.5M
$25.7M
Total assets
$109.1M
$79.7M
Long term debt
$56.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 105.84% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 1.85% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is down 0.66% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
